News | September 23, 2024
AstraZeneca Pharma India to launch Tremelimumab
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The company will now explore a buyer for its manufacturing site and exit in due course
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
Currently, Venkat is Lead – Market Access, India at Pfizer
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Subscribe To Our Newsletter & Stay Updated
